- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04403165
Locus-coeruleus-functie bij normale ouderen en AD-risico (LEAD)
Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife. We have previously demonstrated functional vulnerability of the LC to aging and stress, as well as an association between higher cerebrospinal fluid (CSF) tau and impaired sleep phenomena influenced by the LC. We now aim to test whether LC dysfunction can be measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects sleep architecture and attention. We will test this hypothesis in 30 cognitively normal older adults by performing a full clinical evaluation, one night of polysomnography, a lumbar puncture to obtain cerebrospinal fluid, [11C]MRB PET-MR, and attention testing. This study has the potential to identify a new mechanism by which tau pathology contributes to sleep and attention dysfunction and may provide a new therapeutic target for AD prevention.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
The purpose of this study is three-fold: to test whether lower NET availability in the LC is associated with: first, CSF tau levels typical of preclinical stages of AD (Aim 1); second, reduced REM and spindle density (Aim 2); and third, impaired performance on attention tasks (Aim 3). The goal is to test the overarching hypothesis that LC dysfunction occurs in preclinical AD stages, can be measured with MRB-PET, and translates into impairment of sleep architecture (LC tonic dysfunction) and attention (LC phasic dysfunction).
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
New York
-
New York, New York, Verenigde Staten, 10029
- Icahn School of Medicine Mount Sinai
-
New York, New York, Verenigde Staten, 10016
- NYU Grossman School of Medicine
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Male and female subjects with normal cognition and 55-75 years of age will be enrolled.
- Subjects will be within normal limits on neurological and psychiatric examinations.
- All subjects enrolled will have a CDR of 0. This will be evaluated through a clinical interview administered by a study physician (informant interview will not be required).
- All subjects will have had a minimum of 12 years of education.
Exclusion Criteria:
- History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, stroke, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
- Significant history of alcoholism or drug abuse.
- Significant history of psychiatric illness (e.g., schizophrenia, bipolar, PTSD, or life-long history of major depression).
- Geriatric Depression Scale (short form)>6.
- Insulin dependent diabetes.
- Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological conditions.
- Physical impairment of such severity as to adversely affect the validity of psychological testing.
- Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
- History of a first-degree family member with early onset (age <60 years) dementia.
- Irregular sleep-wake rhythms (based on the actigraphy recordings) or significant OSA (AHI4%≥15).
- Taking Coumadin/warfarin and/or medications affecting cognition or sleep.
- Failure to complete all study visit within 4 months
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Cognitief normale (CN) oudere volwassenen
|
Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics. Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio. PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]O-methylreboxetine ([11C]MRB) to measure NET availability. Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values
Tijdsspanne: Visit 4 (1-4 weeks after LP that occurred on day 14)
|
Visit 4 (1-4 weeks after LP that occurred on day 14)
|
|
|
Total Rapid Eye Movement (REM) Duration (Min)
Tijdsspanne: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Percentage of Time Spent in REM Sleep
Tijdsspanne: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Percentage of REM Runs That Are Less Than 5 Minutes
Tijdsspanne: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
|
Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes
Tijdsspanne: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
|
Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes
Tijdsspanne: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
|
Percentage of Correct Responses on the Picture Test
Tijdsspanne: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)
Tijdsspanne: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
N2 Spindle Density is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Mean Psychomotor Vigilance Test (PVT) Reaction Time
Tijdsspanne: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
PVT measures the reaction speed to a randomly time-occuring visual stimuli, allowing the assessment of several aspects of attention including response times, attention lapses and false starts. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
|
Picture Test Response Time
Tijdsspanne: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System. |
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Levels of Hyperphosphorylated Tau (P-Tau)
Tijdsspanne: Visit 4 (1-4 weeks after LP that occurred on day 14)
|
Levels will be derived from the plasma and reported in pg/mL |
Visit 4 (1-4 weeks after LP that occurred on day 14)
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Ricardo Osorio, NYU Langone Health
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Psychische aandoening
- Neurocognitieve stoornissen
- Dementie
- Tauopathieën
- Neurodegeneratieve ziekten
- Ziekte van Alzheimer
- Onderzoekstechnieken
- Therapeutica
- Exemplaarbehandeling
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Buren
- Chirurgische procedures, operatief
- Biopsie
- Diagnostische technieken, neurologisch
- Spinale punctie
Andere studie-ID-nummers
- 20-00002
- 1R21AG067549-01 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
All of the individual participant data collected during the trial, after deidentification.
IPD-tijdsbestek voor delen
Immediately following publication. No end date.
IPD-toegangscriteria voor delen
The investigator who proposed to use the ricardo.osorio@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .